Wave Life Sciences, Inc.
WVEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeWave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Valued at $957.7M, WVE is a small-cap name in its sector. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Market Cap
$957.7M
Beta
-1.30
P/E (TTM)
—
P/E (Fwd)
-4.08
EPS (TTM)
$-1.08
EPS (Fwd)
$-1.19
ROE
-67.4%
ROA
-33.6%
Cash
$490.6M
Total Debt
$43.6M
Free CF
-$128.8M
52W Change
-35.9%
Annual Financials
Cash vs Debt
Where WVE stands vs its 150-day and 200-day moving averages
As of the August 14, 2026 close, WVE finished 41.18% below its 150-day moving average ($8.84) and 45.38% below its 200-day moving average ($9.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WVE overbought or oversold?
At the August 14, 2026 close, WVE's RSI(14) was 37.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $490.6M in cash and $43.6M in debt, WVE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$128.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -67.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $41.0M (2021) to $42.7M (2025).
The relatively low beta of -1.30 suggests WVE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, WVE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Wave Life Sciences, Inc.'s trajectory.